Chenghua Song

Dr. Chenghua Song

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CSChenghua Song
Chenghua Song
RWRuichao Wen
Ruichao Wen
JZJiaxuan Zhou
Jiaxuan Zhou
XZXiao-Yan Zeng
Xiao-Yan Zeng
ZKZi Kou
Zi Kou
RWRongqian Wu
Rongqian Wu
The increasing resistance of human pathogens promotes the development of novel antimicrobial agents. Due to the physical bactericidal mechanism of membrane disruption, antimicrobial peptides are considered as potential therapeutic candidates without inducing microbial resistance. Scorpion venom-derived peptide, Androctonus amoreuxi Antimicrobial Peptide 1 (AamAP1), has been proved to have broad-spectrum antimicrobial properties. However, AamAP1 can induce hemolysis and shows strong toxicity against mammalian cells. Herein, the antimicrobial activity and mechanism of a novel synthetic antimicrobial peptide, GK-19, derived from AamAP1 and its derivatives, was evaluated. Five bacteria and three fungi were used to evaluate the antimicrobial effects of GK-19 in vitro. Scalded mice models combined with skin and soft tissue infections (SSTIs) were used to evaluate its applicability. The results indicated that GK-19 could not only inhibit Gram-positive and Gram-negative bacterial growth, but also kill fungi by disrupting the microbial cell membrane. Meanwhile, GK-19 showed negligible toxicity to mammalian cells, low hemolytic activity and high stability in plasma. Furthermore, in scalded mice models combined with SSTIs induced by either Methicillin-Resistant Staphylococcus aureus (MRSA) or Candida albicans, GK-19 showed significant antimicrobial and healing effects. Overall, it was demonstrated that GK-19 might be a promising drug candidate in the battle against drug-resistant bacterial and fungal infections.

6 July 2022 in Materials Today Bio
Verified
Journal Article
Open access
CSChenghua Song
Chenghua Song
JZJia Zhang
Jia Zhang
RWRuichao Wen
Ruichao Wen
QLQingshan Li
Qingshan Li
JZJiaxuan Zhou
Jiaxuan Zhou
RWRongqian Wu
Rongqian Wu
Effective systemic treatment for hepatocellular carcinoma (HCC) remains urgently needed. Sorafenib is the first FDA-approved systemic treatment for HCC. However, individual HCC patents’ response to sorafenib varies greatly. How to enhance the anti-HCC effect of sorafenib is still a significant challenge. T cell immunoglobulin mucin-3 (Tim-3) is a newly identified immune checkpoint molecule and a promising target for HCC treatment. Herein, we developed a novel pH-triggered drug-eluting nanoparticle (CC@SR&SF@PP) for simultaneously delivery of Tim-3 siRNA and sorafenib to HCC in situ. By a single emulsification method, a representative HCC targeted-therapeutic drug sorafenib (SF) was encapsulated into the pH-triggered positive-charged mPEG5K-PAE10K (PP) nanoparticles, followed by condensing of negative-charged Tim-3 siRNA. Then, carboxymethyl chitosan (CMCS), an amphoteric polysaccharide with negative charge in the physiological pH and positive charge in the acidic environment of the tumor, was eventually adsorbed onto the surface of nanoparticles. This co-delivery nanoparticle rapidly and specifically accumulated in the tumor site of the liver and enhanced the targeted, specific and multiple release of siRNA and sorafenib. Enhanced Tim-3 siRNA transfected into tumor cells can not only directly inhibit the growth of tumor cells by knock down the expression Tim-3, but also induce the immune response and enhance the recruitment of cytotoxic T cells to kill tumor cells. The following pH-triggered sorafenib release from SF@PP NPs greatly inhibited the tumor proliferation and angiogenesis, resulting in remarkable tumor growth inhibition in a mouse hepatoma 22 (H22) orthotopic tumor model. Thus, co-delivery of Tim-3 siRNA and sorafenib via this novel pH triggered drug-eluting nanoparticle enhances their anti-tumor efficacy. We expect that such combination treatment strategy will have great potential in future clinical applications.

21 December 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
CSChenghua Song
Chenghua Song
RWRuichao Wen
Ruichao Wen
JZJiaxuan Zhou
Jiaxuan Zhou
XZXiaoyan Zeng
Xiaoyan Zeng
ZKZi Kou
Zi Kou
RWRongqian Wu
Rongqian Wu
As a common clinical problem, the therapy of SSTIs is facing growing challenges due to an increase in the number of drug-resistant bacteria and fungi. UV C (UVC) light sterilization has been widely used in all aspects of daily life, but there are very few reports about in vivo therapy using UVC light.

28 April 2022
Verified
Preprint
Open access
CSChenghua Song
Chenghua Song
RWRuiChao Wen
RuiChao Wen
JZJiaxuan Zhou
Jiaxuan Zhou
XZXiaoyan Zeng
Xiaoyan Zeng
ZKZi Kou
Zi Kou
RWRongqian Wu
Rongqian Wu
Background and Purpose: The widespread abuse of antibiotics have led to increasing resistance of many important human pathogens. The urgent need to develop novel antimicrobial therapies has stimulated great interest in antimicrobial peptides as therapeutic candidates for the treatment of infectious diseases. Scorpion venom-derived peptide Androctonus Amoreuxi Antimicrobial Peptide 1 (AamAP1) is a new type of host defense peptide with broad-spectrum but moderate antimicrobial property. Most importantly, AamAp1 has been proved to be highly hemolytic and displays significantly high toxicity against mammalian cells. The aim of this study was to evaluate the antimicrobial activity and mechanism of a novel synthetic antimicrobial peptide GK-19 deriving from AamAP1 and its derivatives. Experimental Approach: Five bacteria and three fungi were used to evaluate the antimicrobial effect of GK-19 in vitro. Mouse models of scalded combined with skin and soft tissue infections were used to evaluate the antimicrobial effect of GK-19 in vivo. Key Results: The results indicated that Gk-19 could not only inhibit Gram-positive and Gram-negative bacterial growth but also kill fungi by permeabilizing microbial membrane. Cellular and in vivo studies proved that GK-19 showed negligible toxicity to mammalian cells, low hemolytic activity and high stability in plasma. Furthermore, in mouse models of scald combined with skin and soft tissue infections induced by either Methicillin-Resistant Staphylococcus Aureus (MRSA) or Candida Albicans, GK-19 showed significant antimicrobial and healing effects. Conclusion and Implications: The novel scorpion venom-derived peptide analogue GK-19 is a promising drug candidate in the battle against multi-resistant bacterial and fungal infections.

1 January 2020 in Chinese Science Bulletin
Verified
Journal Article
Closed access
CSChenghua Song
Chenghua Song
YWYanyun Wang
Yanyun Wang
YLYi Lü
Yi Lü
RWRongqian Wu
Rongqian Wu

28 April 2017 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
ZBZhuxiao Bai
Zhuxiao Bai
YHYurong Huang
Yurong Huang
CSChenghua Song
Chenghua Song
HLHuimin Liu
Huimin Liu
YCYihui Chen
Yihui Chen
XZXin Zhang
Xin Zhang
Patients with acute pulmonary thromboembolism (APTE) have a high short-term mortality rate. The current study aimed to investigate the use of D-dimer in the diagnosis of APTE in suspected APTE patients. All suspected APTE patients were classified into diagnosis or control groups according to the results of a computed tomography pulmonary angiogram. Mann-Whitney U and Kruskal-Wallis H tests were used to evaluate the association between D-dimer values and APTE. Area under the curve (AUC) values and the Youden Index were used to determine D-dimer cut-off levels for the prediction of APTE. The data of 112 suspected APTE patients (54.8% women; mean age, 70.5 years) were analyzed prospectively. There were no significant differences in age (74.5 vs. 73.5 years, P=0.538) or gender distribution (female ratio 56.5 vs. 53.0%, P=0.847) between the diagnosis and control groups. The incidence of symptoms including dyspnea (67.4 vs. 33.3%; P3.32 mg/l fibrinogen equivalent units (FEU) were indicative of APTE and the Youden Index was 0.69. The maximum AUC was 0.87 (95% CI: 0.79–0.92), the sensitivity and specificity were 89.13 and 80.30%, respectively, the positive and negative likelihood ratios were 4.53 and 0.14, respectively, and the positive and negative predictive values were 75.90 and 91.40%, respectively. A D-dimer value <0.60 mg/l FEU was the optimal threshold for excluding APTE diagnosis, with a sensitivity of 100.0% and a specificity of 28.79%. The positive and negative likelihood ratios were 1.40 and 0.00, respectively, and the positive and negative predictive values were 49.50 and 100.00%, respectively. Thus, D-dimer levels, combined with clinical assessment, yield high sensitivity and specificity in diagnosing APTE.